Zobrazeno 1 - 10
of 100
pro vyhledávání: '"Saad Z. Usmani"'
Autor:
Thierry Facon, Gordon Cook, Saad Z. Usmani, Cyrille Hulin, Shaji Kumar, Torben Plesner, Cyrille Touzeau, Nizar J. Bahlis, Supratik Basu, Hareth Nahi, Hartmut Goldschmidt, Hang Quach, Mohamad Mohty, Christopher P. Venner, Katja Weisel, Noopur Raje, Benjamin Hebraud, Karim Belhadj-Merzoug, Lotfi Benboubker, Olivier Decaux, Salomon Manier, Denis Caillot, Jon Ukropec, Huiling Pei, Rian Van Rampelbergh, Clarissa M. Uhlar, Rachel Kobos, Sonja Zweegman
Publikováno v:
Leukemia
Leukemia, 2022, 36 (4), pp.1066-1077. ⟨10.1038/s41375-021-01488-8⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2022, ⟨10.1038/s41375-021-01488-8⟩
Leukemia, 36(4), 1066-1077. Nature Publishing Group
Facon, T, Cook, G, Usmani, S Z, Hulin, C, Kumar, S, Plesner, T, Touzeau, C, Bahlis, N J, Basu, S, Nahi, H, Goldschmidt, H, Quach, H, Mohty, M, Venner, C P, Weisel, K, Raje, N, Hebraud, B, Belhadj-Merzoug, K, Benboubker, L, Decaux, O, Manier, S, Caillot, D, Ukropec, J, Pei, H, van Rampelbergh, R, Uhlar, C M, Kobos, R & Zweegman, S 2022, ' Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma : frailty subgroup analysis of MAIA ', Leukemia, vol. 36, no. 4, pp. 1066-1077 . https://doi.org/10.1038/s41375-021-01488-8
Facon, T, Cook, G, Usmani, S Z, Hulin, C, Kumar, S, Plesner, T, Touzeau, C, Bahlis, N J, Basu, S, Nahi, H, Goldschmidt, H, Quach, H, Mohty, M, Venner, C P, Weisel, K, Raje, N, Hebraud, B, Belhadj-Merzoug, K, Benboubker, L, Decaux, O, Manier, S, Caillot, D, Ukropec, J, Pei, H, Van Rampelbergh, R, Uhlar, C M, Kobos, R & Zweegman, S 2022, ' Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma : frailty subgroup analysis of MAIA ', Leukemia, vol. 36, pp. 1066-1077 . https://doi.org/10.1038/s41375-021-01488-8
Leukemia, 2022, 36 (4), pp.1066-1077. ⟨10.1038/s41375-021-01488-8⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2022, ⟨10.1038/s41375-021-01488-8⟩
Leukemia, 36(4), 1066-1077. Nature Publishing Group
Facon, T, Cook, G, Usmani, S Z, Hulin, C, Kumar, S, Plesner, T, Touzeau, C, Bahlis, N J, Basu, S, Nahi, H, Goldschmidt, H, Quach, H, Mohty, M, Venner, C P, Weisel, K, Raje, N, Hebraud, B, Belhadj-Merzoug, K, Benboubker, L, Decaux, O, Manier, S, Caillot, D, Ukropec, J, Pei, H, van Rampelbergh, R, Uhlar, C M, Kobos, R & Zweegman, S 2022, ' Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma : frailty subgroup analysis of MAIA ', Leukemia, vol. 36, no. 4, pp. 1066-1077 . https://doi.org/10.1038/s41375-021-01488-8
Facon, T, Cook, G, Usmani, S Z, Hulin, C, Kumar, S, Plesner, T, Touzeau, C, Bahlis, N J, Basu, S, Nahi, H, Goldschmidt, H, Quach, H, Mohty, M, Venner, C P, Weisel, K, Raje, N, Hebraud, B, Belhadj-Merzoug, K, Benboubker, L, Decaux, O, Manier, S, Caillot, D, Ukropec, J, Pei, H, Van Rampelbergh, R, Uhlar, C M, Kobos, R & Zweegman, S 2022, ' Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma : frailty subgroup analysis of MAIA ', Leukemia, vol. 36, pp. 1066-1077 . https://doi.org/10.1038/s41375-021-01488-8
In the phase 3 MAIA study of patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) versus lenalidomide/dexamethasone (Rd). We present a
Autor:
Hans C. Lee, Saad Z. Usmani, Robert M. Rifkin, Dasha Cherepanov, Evangelos Terpos, Faith E. Davies, Dorothy Romanus, Antonio Palumbo, Aditya Raju, Jesus G. Berdeja, Dawn Marie Stull, Noemi Puig, Jorge Vela-Ojeda, Rafat Abonour, Xavier Leleu, Hui Huang, Ajai Chari, Eileen Farrelly, Mario Boccadoro, Gordon Cook, Katja Weisel, Gareth J. Morgan, Caitlin Costello, Jeffrey A. Zonder, Marlo Blazer, Michael A. Thompson, Roman Hájek
Publikováno v:
Annals of Hematology
Multiple available combinations of proteasome inhibitors, immunomodulators (IMIDs), and monoclonal antibodies are shifting the relapsed/refractory multiple myeloma (RRMM) treatment landscape. Lack of head-to-head trials of triplet regimens highlights
Autor:
Peter M. Voorhees, Michael Rosenzweig, S. Vincent Rajkumar, Robert Z. Orlowski, Jeffrey A. Zonder, Sandi Fredette Hita, Jason Valent, Natalie S. Callander, Rachael Sexton, Paul G. Richardson, Antje Hoering, Saad Z. Usmani, Swog Trial Investigators, Sikander Ailawadhi, Brian G.M. Durie, Madhav V. Dhodapkar, Todd M. Zimmerman, Brea Lipe
Publikováno v:
The Lancet Haematology. 8:e45-e54
Summary Background The introduction of immunomodulatory agents, proteasome inhibitors, and autologous haematopoietic stem-cell transplantation has improved outcomes for patients with multiple myeloma, but patients with high-risk multiple myeloma have
Autor:
Daniel L. Thompson, Allison L. Martin, Manisha Bhutani, Donald C Moore, Barry Paul, Shebli Atrash, Peter M. Voorhees, Justin Arnall, Jordan Robinson, Saad Z. Usmani, Ami Ndiaye
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e777-e781
Background Daratumumab is an anti-CD38 monoclonal antibody indicated for the treatment of multiple myeloma. Infusion-related reactions (IRRs) are among the most common adverse events associated with daratumumab. IRRs are most common with the first in
Autor:
Saad Z. Usmani, Annette Lam, Bareng A. S. Nonyane, Eric M Maiese, Shaji Kumar, Brian G.M. Durie, Thierry Facon, Rachel Kobos, Eric M. Ammann
Publikováno v:
American Journal of Hematology
Daratumumab in combination with lenalidomide‐dexamethasone (D‐Rd) recently received FDA approval for the treatment of transplant‐ineligible patients with newly diagnosed multiple myeloma (NDMM). The present PEGASUS study compared progression‐
Autor:
Martin Kaiser, Baldeep Wirk, Monika Engelhardt, Bruno Paiva, Laurent Garderet, S. Vincent Rajkumar, Maria-Victoria Mateos, Philippe Moreau, Carlos Fernández de Larrea, Robert A. Kyle, Jo Caers, Wilson I. Gonsalves, Hermann Einsele, Hartmut Goldschmidt, Giampaolo Merlini, Suzanne Lentzch, Ashraf Badros, Saad Z. Usmani, Joan Bladé, Pellegrino Musto, Fredrik Schjesvold, Pieter Sonneveld, Jesús F. San Miguel, Laura Rosiñol, Gösta Gahrton, Patrick Hayden, Enrique M. Ocio, Brian G.M. Durie, Sascha A. Tuchman
Publikováno v:
Blood Cancer J . 2021 Dec 2;11(12):192
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Blood Cancer Journal
Blood Cancer Journal, Nature Publishing Group, 2021, 11 (12), ⟨10.1038/s41408-021-00587-0⟩
Blood Cancer Journal, Vol 11, Iss 12, Pp 1-5 (2021)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Blood Cancer Journal, 11(12):192. Nature Publishing Group
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Blood Cancer Journal
Blood Cancer Journal, Nature Publishing Group, 2021, 11 (12), ⟨10.1038/s41408-021-00587-0⟩
Blood Cancer Journal, Vol 11, Iss 12, Pp 1-5 (2021)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Blood Cancer Journal, 11(12):192. Nature Publishing Group
Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position pa
Publikováno v:
Bone Marrow Transplantation. 56:9-19
Despite a sea change in the therapeutic landscape, multiple myeloma (MM), a cancer of antibody producing plasma cells, remains incurable requiring continued intervention for disease control. In this context, chimeric antigen receptor (CAR) T cell the
Autor:
Ruben Niesvizky, Saurabh Chhabra, Chatchada Karanes, Robert F. Cornell, Yihua Lee, Saad Z. Usmani, Jeffrey Matous, Robert K. Stuart, Larry D. Anderson, Jason Valent, Cristina Gasparetto, Zeena Salman, Emily Liu, Ajai Chari, Matthew A. Lunning, Chaim Shustik, Saulius Girnius
Publikováno v:
Hematological Oncology
Patients with multiple myeloma (MM) inevitably relapse on initial treatment regimens, and novel combination therapies are needed. Ibrutinib is a first‐in‐class, once‐daily inhibitor of Bruton's tyrosine kinase, an enzyme implicated in growth an
Publikováno v:
Leukemia. 34:1-20
Extramedullary multiple myeloma (EMM) is an aggressive subentity of multiple myeloma, characterized by the ability of a subclone to thrive and grow independent of the bone marrow microenvironment, resulting in a high-risk state associated with increa
Autor:
Lotfi Benboubker, Saad Z. Usmani, Shinsuke Iida, Jordan M. Schecter, Maria-Victoria Mateos, Christopher Chiu, Lisa O'Rourke, Ludek Pour, Michele Cavo, Nizar J. Bahlis, Gordon Cook, Jacob P. Laubach, Katja Weisel, Andrew Spencer, Sung-Soo Yoon, Ajay K. Nooka, Meletios A. Dimopoulos, Xiang Qin, Jon Ukropec
Publikováno v:
Haematologica
The phase 3 POLLUX and CASTOR studies demonstrated superior benefit of daratumumab plus lenalidomide/dexamethasone or bortezomib/dexamethasone in relapsed/refractory multiple myeloma. Efficacy and safety of daratumumab was analyzed according to age g